ArticleFrontiers in oncology2024
Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates. The aim of this study was to compare 3-year follow-up data for patients with esophageal malignancy who achieved PCR through neoadjuvant chemotherapy (nCRT) and to compare the findings with those of neoadjuvant immunotherapy plus chemotherapy (nICT). Methods: This retrospective study included 85 patients with esophageal cancer who underwent surgical resection following nCRT (n=47) or nICT (n=38) between January 1, 2016 and January 1, 2020 at Fujian Medical University Union Hospital and Gaozhou People's Hospital. Propensity score matching was used to match baseline data and reduce bias between the patient groups. Data during the neoadjuvant treatment and perioperative periods were compared, and follow-up was performed to evaluate differences in 3-year survival rate and recurrence-free survival. Results: After propensity score matching, 28 nCRT patients and 38 nICT patients were included. During neoadjuvant therapy, the nCRT group had higher incidences of leukopenia and neutropenia than did the nICT group. No significant differences were observed in the incidences of hemoglobin decrease, platelet decrease, liver function damage, elevated serum creatinine, diarrhea, radioactive pneumonia or immunotherapy-related pneumonia, and esophageal perforation. The nCRT group had fewer lymph node dissections and lymph node stations. Postoperative lung infection (50.00%) was significantly higher in the nICT group than in the nCRT group (25.00%). The 3-year survival rates were 97.37% and 85.71% in the nICT and nCRT groups, respectively; the 3-year recurrence-free survival rate was significantly lower in the nCRT group (82.14%) than in the nICT group (97.37%, P=0.02). Conclusions: These findings suggest that patients with esophageal cancer who achieve PCR after nICT treatment may have lower rates of disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.